The partnership between the Danish pharmaceutical giant and the splashy telehealth firm Hims & Hers was strained from the ...

Big Pharma hates the telehealth startup. Meme-stock day traders love it. Why CEO Andrew Dudum won’t stop selling GLP-1s, no ...

Hims & Hers Health will continue offering low-cost compounded weight-loss shots even after Novo Nordisk terminated their partnership over alleged “deceptive marketing,” CEO Andrew Dudum said in his ...

Investing.com -- Hims & Hers CEO Andrew Dudum has shared new information about the company’s terminated partnership with Novo Nordisk (NYSE: NVO ), which ended in June 2025, in an interview with The ...

Hims & Hers Health CEO Andrew Dudum said that the telehealth platform will continue to sell a compounded version of semaglutide. Read more here.

Hims & Hers CEO Andrew Dudum, in a post on X, accused Novo of attempting to control clinical standards at Hims & Hers to steer the company’s patients toward Wegovy. Featured Video.

Hims & Hers Health CEO Andrew Dudum said the company will continue to sell cheap weight-loss shots despite Novo Nordisk A/S ending their distribution partnership over "deceptive marketing" practices.

Andrew Dudum, founder and CEO of Hims & Hers, posted a response statement on X that said he was “disappointed to see Novo Nordisk management misleading the public. ...